Pharming Group NV purchased the remaining intellectual property assets of PPL Therapeutics plc from London-based Innovation Development Ltd., for what Chief Science and Technology Officer Frank Pieper called "a relatively small sum." (BioWorld International)

Pharming Group NV purchased the remaining intellectual property assets of PPL Therapeutics plc from London-based Innovation Development Ltd., for what Chief Science and Technology Officer Frank Pieper called "a relatively small sum." (BioWorld International)

Evolva SA raised €12 million in a Series A round to further develop its Watchmaker platform, which employs yeast artificial chromosomes and flow cytometry for the synthesis and selection of novel compounds. (BioWorld International)

Evolva SA raised €12 million in a Series A round to further develop its Watchmaker platform, which employs yeast artificial chromosomes and flow cytometry for the synthesis and selection of novel compounds. (BioWorld International)